Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $18.33, for a total value of $714,870.00. Following the completion of the sale, the chief executive officer owned 816,317 shares of the company’s stock, valued at $14,963,090.61. This trade represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total value of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $20.10, for a total value of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total value of $717,600.00.

CeriBell Stock Down 1.3%

CeriBell stock opened at $18.15 on Friday. The stock has a market capitalization of $688.61 million, a PE ratio of -11.13 and a beta of 0.84. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33. The business has a 50 day simple moving average of $18.98 and a 200-day simple moving average of $19.69. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. On average, analysts anticipate that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CBLL. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. Canaccord Genuity Group dropped their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average target price of $22.20.

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in CeriBell during the first quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its stake in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter worth $33,000. CWM LLC boosted its stake in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.